Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study - Fraticelli, P; Gabrielli, B; Pomponio, G (Arthritis Res Ther, 2014)
, et al; Imatinib in Scleroderma Italian Study Group.